Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab for DMF Non-Responders in Plaque Psoriasis (TRANSITION)
NCT04263610Phase 4Completed
- Sponsor
- Almirall
- Start
- Sep 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of tildrakizumab in plaque psoriasis (3 arms), sponsored by Almirall. Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index 75 at 40 weeks. Started Sep 2019; status: completed.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04263610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263610.